Cancer Advisor Treatment Selector v2.0.1 (2026)

By Editorial Team

Cancer Treatment Selector

Build a personalized treatment discussion map based on cancer type, disease extent, biomarkers, previous treatment and treatment goals.

Cancer Treatment Selector v2.0.1
Step 1 of 8

1. What type of cancer?

Select the cancer type that best matches your diagnosis. *

Why this matters: Treatment is highly cancer-specific. The same biomarker or drug can have very different clinical meaning in different cancers.

2. What is the disease extent?

Select the option that best describes your current diagnosis. *

Early / localized
Cancer appears confined to the organ or primary site.
Regional
Cancer has spread to nearby lymph nodes or surrounding structures.
Metastatic / Stage IV
Cancer has spread to distant organs or sites.
Recurrent
Cancer has returned after previous treatment.
I don't know
I need help understanding the stage or extent.

3. What is the pathology?

Select any descriptions that appear on your pathology report.

Adenocarcinoma
A common gland-forming cancer type.
Squamous cell carcinoma
A squamous-cell cancer subtype.
Carcinoma
Pathology identifies a carcinoma.
Sarcoma
Cancer arising from connective tissues.
Neuroendocrine
Neuroendocrine differentiation or tumor.
I don't know
I need help understanding pathology.

4. What treatment have you had?

Select all that apply.

Surgery
Surgery to remove the primary tumor or metastases.
Radiation
External beam or other radiotherapy.
Chemotherapy
Cytotoxic chemotherapy.
Immunotherapy
Checkpoint inhibitor or other immune-based treatment.
Targeted therapy
Treatment directed at a molecular alteration.
Hormone therapy
Endocrine or androgen-directed treatment.
No treatment yet
Newly diagnosed or treatment has not started.

5. Which biomarkers are known?

Select biomarkers that appear on your pathology, genomic or molecular testing.

PD-L1
PD-L1 expression / TPS / CPS.
MSI-H / dMMR
Microsatellite instability or mismatch repair.
TMB
Tumor mutation burden.
HER2
HER2 overexpression or amplification.
BRCA
BRCA1 / BRCA2 alteration.
HRD
Homologous recombination deficiency.
EGFR
EGFR mutation.
ALK
ALK alteration or fusion.
ROS1
ROS1 fusion.
BRAF
BRAF alteration.
KRAS
KRAS mutation.
RET
RET alteration or fusion.
MET
MET alteration / exon 14.
NTRK
NTRK fusion.
Biomarkers unknown
I do not know my biomarker results.
Important: A biomarker does not automatically mean that a particular treatment is appropriate. Cancer type, stage, treatment line, assay and clinical context all matter.

6. What is happening now?

Select the situation that best describes your current treatment status. *

Newly diagnosed
I am planning my initial treatment.
Currently in treatment
I am currently receiving cancer treatment.
Responding / stable
Current treatment appears to be working or disease is stable.
Progression
Scans or tests indicate cancer is growing despite treatment.
Relapse / recurrence
Cancer has returned after a period of control.

7. What do you want to understand?

Select the area you want the treatment map to emphasize. *

Standard treatment
Surgery, radiation, chemotherapy, targeted therapy or hormone therapy.
Immunotherapy
Whether checkpoint inhibitors or immune-based treatment may be relevant.
Precision oncology
Biomarkers, genomic profiling and targeted treatment.
Treatment resistance
What to investigate when treatment stops working.
Clinical trials
Investigational treatments and biomarker-matched trials.
Supportive / integrative care
Nutrition, exercise, symptoms and complementary approaches.

Your Cancer Treatment Map

Your selections have been used to organize treatment and biomarker questions.

1. Established Treatment Categories

2. Precision Oncology & Biomarkers

3. Clinical Trials & Treatment Resistance

4. Supportive & Integrative Care

5. Questions to Ask Your Oncology Team

Cancer Advisor resources

PD-L1 vs TMB vs MSI-H
PD-L1 Explained for Patients
Tumor Mutation Burden Explained
MSI-H and Immunotherapy
Why Some Patients Respond to Immunotherapy
Radiotherapy + Immunotherapy
Medical disclaimer: This tool is an educational decision-support tool and is not a diagnostic device or a substitute for medical advice. It does not prescribe a treatment, determine eligibility for a drug, or predict an individual patient's outcome. Cancer treatment decisions should be made with a qualified oncology team using the complete pathology, staging, biomarker results, previous treatment history, overall health and current clinical guidelines. Do not stop, delay or replace prescribed cancer treatment based on this tool.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Medically Reviewed | Last updated on June 28, 2026. Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. Repurposed Cancer Therapies Case Reports Explorer Interactive tracking dashboard compiling 766 reported case studies across 21 fields. Click any card to jump directly to its dedicated arti...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Quick Answer The supplements with the strongest human research behind them are vitamin D3 (paired with K2 and magnesium) , curcumin , omega-3 fatty acids , and green tea EGCG — each backed by multiple randomized controlled trials or meta-analyses, though results are mixed rather than uniformly positive. Melatonin looked promising in older, smaller trials, but the largest randomized trial to date found no overall survival benefit. No supplement replaces conventional cancer treatment, and a few — high-dose beta-carotene, vitamin E, and high-dose B6/B12 — have been linked to increased cancer risk in specific groups. Antioxidant supplements are generally discouraged during chemotherapy or radiotherapy unless a doctor directs otherwise. This is an educational overview, not personal medical advice — always loop in your oncology team before starting anything new. Disclosure: Some links in this article are affiliate links (including The Wellness Company and Amazon Associates). If ...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Last revised: July 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published p...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

By Editorial Team
Image
Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: July 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the preclin...
Read more

30 Best Alternative Cancer Treatments 2026: Proven Interventions

By Editorial Team
Image
Updated July 2026 · Evidence-Ranked Edition This article has been reorganised to rank all 30 integrative cancer interventions by the quality and quantity of available evidence — from randomised controlled trial data down to preclinical laboratory findings. Use this as a structured reference, not a treatment guide. Always consult a qualified healthcare professional before initiating any therapy. ⚠️ Medical Disclaimer: This content is for educational purposes only. Nothing in this article should be used as the basis for initiating, modifying, or discontinuing any cancer treatment without guidance from your treating oncologist or physician. The interventions described here are not approved cancer treatments unless explicitly stated. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024 Introduction Most mainstream guides to “alternative cancer treatments”—including the widely cited Mayo Clinic overview—focu...
Read more

Fenbendazole, Ivermectin and Mebendazole for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Last updated: 15 July 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated July 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreatic cancer have been published as of July 2026. ...
Read more

Archive

Show more